Takeda Pharmaceutical Company L
TAK
Positions held
Your positionsTAK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Takeda's strong gross margin of 66.7% indicates efficient production and pricing power in the specialty drug market.
- Revenue increased by 11% compared to the prior quarter, reaching $1.2 trillion.
- Operating margin expanded to 16.5%, showcasing improved operational efficiency.
- The company's net income for 2026 is projected to be negative at -$152.39 million, indicating ongoing profitability challenges.
- Earnings growth has declined by 9.8%, reflecting potential issues in sustaining profitability.
- The debt-to-equity ratio stands at 73.25, suggesting high leverage that may pose risks in volatile markets.
Fundamentals
| Market cap | $59.16B | Enterprise value | $5.14T | Trailing P/E | — | Forward P/E | 34.94 |
| PEG | 0.41 | Price / book | 1.23 | Beta | 0.10 | Dividend yield | 3.33% |
| Revenue growth | 10.2% | Earnings growth | -9.8% | Gross margin | 64.5% | Operating margin | 16.4% |
| Profit margin | -3.5% | ROE | -2.3% | ROA | 2.7% | Debt / equity | 0.73 |
| Current ratio | 1.14 | Free cash flow | $541.44B | Analyst recommendation | strong_buy | Mean target | $21.96 |
| 52w high | $19.10 | 52w low | $12.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.2T | $1.1T | $1.2T | $1.1T | $1.1T |
| Op margin | 16.5% | 3.8% | 14.2% | 6.2% | 16.7% |
| Net income | $113.2B | -$368.5B | $103.6B | -$11.8B | $124.2B |
| Gross margin | 66.7% | 62.9% | 66.3% | 65.8% | 65.2% |
| Gross profit | $813.2B | $688.8B | $790.5B | $732.7B | $722.0B |
| Operating income | $201.4B | $42.1B | $168.8B | $69.0B | $184.6B |
- Revenue +11% vs prior quarter ($1.2T vs $1.1T).
- Gross margin 66.7% (was 62.9% prior quarter).
- Operating margin expanded to 16.5%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $4.5T | $4.6T | $4.3T | $4.0T | — |
| Op margin | 10.3% | 10.2% | 7.3% | 14.6% | — |
| Net income | -$152.4B | $107.9B | $144.1B | $317.0B | — |
| Gross margin | 65.1% | 65.5% | 66.5% | 69.1% | — |
| Gross profit | $2.9T | $3.0T | $2.8T | $2.8T | — |
| Operating income | $464.5B | $466.4B | $309.9B | $587.8B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026
2026-10-07 · Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading
2026-10-06 · Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
2026-10-01 · Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run
2026-10-01 · Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
2026-09-30 · Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
2026-09-30 · Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
2026-09-30 · Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
2026-09-29 · Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
2026-09-29 · Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium
Price (daily)
Full chart · RSI · MACD · patterns